Morgan Stanley analyst Tejas Savant maintained a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $42.00. The company’s shares closed yesterday at
Morgan Stanley analyst Tejas Savant maintained a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $42.00. The company’s shares closed yesterday at
Bernstein lowered the firm’s price target on Guardant Health (GH) to $35 from $40 and keeps an Outperform rating on the shares. With the large, diversified tools companies taking a